134 related articles for article (PubMed ID: 37419372)
1. EBV-encoded miRNAs BHRF1-1 and BART2-5p aggravate post- transplant lymphoproliferative disorder via LZTS2-PI3K-AKT axis.
Ji H; Yang T; Li C; Zhu Y; Zheng Z; Zhang J; Liu Y; Gao Y; Wu H; Jiang J; Yong J; Chen M; Tang Y; Xia Q; Xue F
Biochem Pharmacol; 2023 Aug; 214():115676. PubMed ID: 37419372
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus microRNA miR-BART2-5p accelerates nasopharyngeal carcinoma metastasis by suppressing RNase Ⅲ endonuclease DICER1.
Wu Y; Zhang X; Liu C; Li Z; Wen Y; Zheng R; Xu C; Tian J; Wei L; Wang J; Yan Q; Zheng X; Ma J
J Biol Chem; 2023 Sep; 299(9):105082. PubMed ID: 37495108
[TBL] [Abstract][Full Text] [Related]
3. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus miR-BART2-5p and miR-BART11-5p regulate cell proliferation, apoptosis, and migration by targeting RB and p21 in gastric carcinoma.
Zhao MH; Liu W; Zhang X; Zhang Y; Luo B
J Med Virol; 2023 Jan; 95(1):e28338. PubMed ID: 36418188
[TBL] [Abstract][Full Text] [Related]
5. Plasma EBV microRNAs in paediatric renal transplant recipients.
Hassan J; Dean J; De Gascun CF; Riordan M; Sweeney C; Connell J; Awan A
J Nephrol; 2018 Jun; 31(3):445-451. PubMed ID: 29185211
[TBL] [Abstract][Full Text] [Related]
6. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
7. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM
Front Immunol; 2022; 13():994552. PubMed ID: 36304469
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the expression of the Epstein-Barr virus (EBV) anti-apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV-related lymphoid diseases.
Nicholls J; Kremmer E; Meseda CA; Mackett M; Hahn P; Gulley ML; Brink A; Swinnen LJ; Greenspan J; De Souza Y; Grässer F; Sham J; Ng MH; Arrand JR
J Med Virol; 2001 Sep; 65(1):105-13. PubMed ID: 11505451
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
10. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
14. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
15. An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.
Skinner CM; Ivanov NS; Barr SA; Chen Y; Skalsky RL
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794034
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus miRNA BART2-5p Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing RND3.
Jiang C; Li L; Xiang YQ; Lung ML; Zeng T; Lu J; Tsao SW; Zeng MS; Yun JP; Kwong DLW; Guan XY
Cancer Res; 2020 May; 80(10):1957-1969. PubMed ID: 32060148
[TBL] [Abstract][Full Text] [Related]
17. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
[No Abstract] [Full Text] [Related]
18. A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.
Fink SE; Gandhi MK; Nourse JP; Keane C; Jones K; Crooks P; Jöhrens K; Korfel A; Schmidt H; Neumann S; Tiede A; Jäger U; Dührsen U; Neuhaus R; Dreyling M; Borchert K; Südhoff T; Riess H; Anagnostopoulos I; Trappe RU
Am J Transplant; 2014 Nov; 14(11):2577-87. PubMed ID: 25130212
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
